Stephen FellerCLEVELAND, April 19 (UPI) — Daily aspirin use can reduce risk for bile duct cancer, researchers at the Mayo Clinic report in a recent study.
Conditions: Cholangiocarcinoma; Biliary Tract Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification Intervention: Drug: Trastuzumab Sponsor: Changhoon Yoo Not yet recruiting
ConclusionsRLS can be performed for primary hepatobiliary malignancies with long-term oncologic outcomes comparable to published open and laparoscopic data.
Circulating tumor cells (CTC) enter the blood from many carcinomas and represent a likely source of metastatic dissemination. In contrast to the peripheral circulation, KRAS mutation- positive CTC thrive in the portal venous blood of patients with pancreatic ductal adenocarcinoma (PDAC). To analyze the essential interactions that contribute to carcinoma CTC growth and immune resistance, portal venous blood was collected during pancreatico-duodenectomy in 41 patients with peri-ampullary pathologies (PDAC = 11; ampullary adenocarcinoma (AA) = 15; distal cholangiocarcinoma (CC) =&nbs…
Conclusions: Although FDG-PET may be useful for assessing tumor
progression factors, such as lymph node metastasis, it cannot accurately detect precancerous lesions, such as BilIN
and IPNB without invasive carcinoma.
PMID: 30049183 [PubMed – in process]
Authors: Kaewpitoon N, Kaewpitoon SJ, Meererksom T, Chan-Aran S, Sangwalee W, Kujapun J, Norkaew J, Chuatanam J, Ponpimai S, Pothipim M, Padchasuwan N, Tongtawee T, Matrakool L, Panpimanmas S, Loyd RA, Wakkhuwatthapong P
The carcinogenic liver fluke, Opisthorchis viverrini, is a serious health problem in Southeast Asia where infection
is associated with cholangiocarcinoma, a major cause of death in Thailand. This cross-sectional study aimed to screen
for O. viverrini infection among a Thai rural population of 560 individuals from Nakhon Ratchasima, Khonkaen, and
Chaiyaphum provinces with a verbal screening…
AbstractData on the effectivness of PIPAC in patients with peritoneal metastases of pancreaticobiliary origin is scarce. We here present further proof of treatment efficacy in this subset of patients. Repetitive PIPAC treatment with low-dose cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 body surface area every 6 weeks and prospective data collection. Documentation included microscopic histological regression, median overall survival and treatment-related adverse events. Twelve patients with a median age of 57 years (range 43–78 years) were included. Six patients suffered from pertioneal metasta…
AbstractCholangiocarcinoma (CCA) is a cancer of the bile ducts that is associated with poor prognosis and poor treatment outcome. Approximately one-third of CCA patients can undergo surgery, but the recurrence rate is high and chemotherapy often cannot satisfactorily prolong survival. Cellular immunotherapy based on adoptive T-cell transfer is a potential treatment for CCA; however, the development of this technology and the search for an appropriate tumor-associated antigen are still ongoing. To enhance the cytotoxic activity of effector T cells against CCA, we developed self-differentiated monocyte-derived dendritic cell…
In this report, trends in liver cancer death rates are examined by sex, race and Hispanic origin, and age group from 2000 through 2016 for adults aged 25 and over. Death rates in 2016 by state and the District of Columbia (D.C.) are also presented.
PMID: 30044212 [PubMed – in process]
This article provides an overview of intrahepatic and extrahepatic cholangiocarcinoma, including identification of risk factors, differences in treatment approaches, palliation of symptoms, and insight into commonly asked questions.
METHODS: A comprehensive review of the current literature regarding incidence, prevalence, and treatment of cholangiocarcinoma was conducted.
FINDINGS: Nursing literature regarding cholangiocarcinoma is scarce. Studies that focus on nursing care, symptom management, and nursing management of patients with biliary obstruction are needed. Nutrition and palliative care management of pati…
Cholangiocarcinoma (CCA) is a destructive malignancy with limited responsiveness to conventional chemotherapy. Although angiotensin receptor blockers (ARBs) have gained attention for their potential anticancer activity, little is known about their effects on CCA. The transcriptional co-activator, Yes-associated protein (YAP) is a critical oncogene in several cancers, including CCA. Following recent evidence showing that YAP is regulated by angiotensin II (AT-II), we investigated the effects of an ARB, losartan, on two human CCA cell lines (KKU-M213 and HuCCT-1) with regards to YAP oncogenic regulation.